Home/Pipeline/T3D-959 (Future)

T3D-959 (Future)

Huntington's Disease

Pre-clinical / ResearchActive

Key Facts

Indication

Huntington's Disease

Phase

Pre-clinical / Research

Status

Active

Company

T3D Therapeutics

About T3D Therapeutics

T3D Therapeutics is pioneering a novel approach to treating Alzheimer's disease by targeting brain 'starvation'—a core metabolic dysfunction characterized by impaired glucose and lipid metabolism. Its lead candidate, T3D-959, is a first-in-class, orally administered dual nuclear receptor agonist that has completed a Phase 2 trial (PIONEER) in mild-to-moderate Alzheimer's patients. The company is positioning itself as a potential disruptor in the neurodegenerative disease space, with a secondary focus on Huntington's Disease, and is actively advancing its clinical program based on recent biomarker and cognitive data presentations.

View full company profile

Therapeutic Areas

Alzheimer's Disease Huntington's Disease Neurodegenerative Diseases

Other Huntington's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
Huntington's Disease Program	Rumi Scientific	Pre-clinical	Active
SOM3355	SOM Biotech	Phase 3	Active
LETI-101	ElevateBio	Preclinical	Active
Somatic Expansion Inhibitor Program	LoQus23 Therapeutics	Preclinical	Active
Preclinical Program	Excision BioTherapeutics	Preclinical	Active
NA-841	Biomed	Phase 2A	Active
HD mAb Therapy	HD Immune	Pre-clinical	Active
TT-P34	Teitur Trophics	Pre-clinical	Active
INT41	Vybion	Pre-clinical	Active
Huntington's Program	reMYND	Pre-clinical	Active
Pridopidine	Prilenia Therapeutics	Phase 3	Active